Illumina, Inc.
ILMNHealthcareNASDAQDiagnostics & Research · Last scanned Jul 18, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Illumina, Inc. focuses on Diagnostics & Research services and products. Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company carries a $28.24B market cap, placing it firmly in the large-cap category. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.
Market Cap
$28.24B
Beta
1.47
P/E (TTM)
34.63
P/E (Fwd)
31.46
EPS (TTM)
$5.39
EPS (Fwd)
$5.93
ROE
33.8%
ROA
8.7%
Cash
$1.16B
Total Debt
$2.54B
Free CF
$845.6M
52W Change
94.1%
Annual Financials
Cash vs Debt
On the balance sheet, ILMN has $1.16B in cash with $2.54B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Annual free cash flow of $845.6M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 33.8%, which is exceptionally high for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 8.7% suggests reasonable efficiency in deploying the company's asset base. Revenue has been relatively flat, moving from $4.58B (2022) to $4.34B (2025).
As with any equity investment, ILMN carries market risk, sector-specific risk, and company-specific risk that investors should evaluate in the context of their own portfolios. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Illumina, Inc. and its sector.